在生殖尿路癌症中mRNA疫苗的进展
You-Min Shen1, Fang-Ning Wan1, Hua Xu1
1Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Shanghai Genitourinary Cancer Institute, Shanghai 200032, China.
Biochimica et biophysica acta. Reviews on cancer
|August 22, 2025
概括
传递器RNA (mRNA) 技术正在彻底改变癌症治疗, 这篇评论探讨了mRNA
科学领域:
- 瘤学和免疫学
- 生物技术和基因工程
背景情况:
- 随着成本的下降,信使RNA (mRNA) 技术在医疗干预中得到了快速发展.
- 与传统方法不同,mRNA疫苗利用下一代测序 (NGS) 进行个性化设计.
- mRNA技术在癌症治疗中提供了多方面的应用,包括抗原编码,细胞因子递送,基因疗法和基于T细胞的疗法.
研究的目的:
- 审查mRNA疫苗在生殖尿路癌症中的开发和应用.
- 总结各种合成mRNA类型和高效的传递系统.
- 讨论基于mRNA的癌症疗法的临床前和临床研究,挑战和未来的机会.
主要方法:
- 在生殖尿路癌症中对mRNA疫苗进行临床前和临床研究的文献综述.
- 合成mRNA类型,输送系统和治疗策略的分析.
- 考察现有障碍和未来的前景.
主要成果:
- 基于mRNA的方法在临床前癌症研究中显示出显著的前景,其中一些方法已进入临床试验.
- 已批准的mRNA疫苗的安全性和有效性支持对mRNA疗法的兴趣日益增长.
- 在未来的癌症治疗中,mRNA技术将发挥至关重要的作用.
结论:
- mRNA技术为开发新型癌症治疗提供了强大的平台,特别是在生殖尿道癌症中.
- 对各种mRNA类型,输送系统和临床应用的持续研究至关重要.
- 克服目前的障碍将释放基于mRNA的疗法的全部潜力,从而改善患者的治疗结果.
相关概念视频
Cancer Vaccines
509
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
509
Microorganisms in Medicine and Therapeutics
314
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
314
Rous Sarcoma Virus (RSV) and Cancer
5.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
5.4K
Mechanisms of Retrovirus-induced Cancers
5.3K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
5.3K
Initiation of Translation
34.5K
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
34.5K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K


